BioNTech SE (BNTX)

業務介紹

BioNTech SE是一家生物技術公司，致力於開發和商業化用於癌症和其他傳染性疾病的免疫療法。該公司正在開發FixVac產品候選藥，包括BNT111，該藥正在進行第二期臨床試驗，用於晚期黑色素瘤；BNT112正在進行第一/二期臨床試驗，用於攝護腺癌；BNT113正在進行第二期臨床試驗，用於治療HPV陽性的頭頸部癌症；BNT114正在進行第一期臨床試驗，用於三陰性乳腺癌；BNT115正在進行第一期臨床試驗，用於卵巢癌；以及BNT116，一種用於非小細胞肺癌的臨床前產品。它還開發了新抗原特異性免疫療法，如Autogene cevumeran（BNT122），該藥正在進行第二期臨床試驗，用於一線黑色素瘤，以及進行第1a/1b期臨床試驗，用於治療多種實體腫瘤；包括SAR441000的mRNA腫瘤內免疫療法正在進行第一期臨床試驗，用於實體腫瘤；以及BNT141和BNT142正在進行第一期臨床試驗，用於治療多種實體腫瘤。此外，該公司還開發了RiboCytokines，包括BNT151、BNT152和BNT153，用於治療實體腫瘤；嵌合抗原受體T細胞免疫療法，如BNT211用於治療多種實體腫瘤，以及BNT221用於其他癌症；以及檢查點免疫調節劑，包括GEN1046和GEN1042，正在進行第一/二期臨床試驗，用於治療實體腫瘤。此外，該公司還開發了BNT321，一種用於胰腺癌的IgG1單克隆抗體，正在進行第二期臨床試驗；BNT411，一種用於實體腫瘤的小分子免疫調節劑產品候選藥；預防COVID-19和流感的疫苗；以及傳染性疾病免疫療法和罕見疾病蛋白質替代療法。該公司與Genentech, Inc.、Sanofi S.A.、Genmab A/S、Pfizer Inc.、上海復星醫藥（集團）有限公司和Regeneron Pharmaceuticals, Inc.合作。BioNTech SE成立於2008年，總部位於德國邁因茨。

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

公司網址

https://www.biontech.de